Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Intralesional Therapy for Melanoma: Two Steps Forward and One Step Back?

Release Date: March 24, 2009| Expiration Date: March 24, 2010
1.25 AMA PRA Category 1 Credit(s)™| Mar 13, 2009, New York, NY

Lecture Overview

Currently, there is no accepted standard therapy for patients with advanced locoregional melanoma who are facing a poor prognosis and the possibility of developing large and painful lesions. The Intralesional Therapy for Melanoma: Two Steps Forward and One Step Back? symposium will focus on intralesional therapy as a strategy for both local and potentially systemic control of melanoma. A variety of agents that are being developed to address this continuing medical need, including chemotherapy and immunotherapy options, will be discussed. Clinical trials investigating novel intralesional therapy for melanoma that are currently recruiting patients will also be presented.

This educational program is directed toward medical oncologists, surgical oncologists, and dermatologists involved in basic science research, clinical research, and clinical practice. Fellows, oncology nurses, oncology physician assistants, and pharmacists who are interested in the treatment of melanoma are also invited to participate.

Upon completion of this educational activity, you should be able to:

  • Discuss the role of intratumoral therapy in the treatment of locoregional melanoma
  • Assess investigational agents for advanced locoregional disease, including chemotherapy and various immunotherapy options
  • Identify appropriate patients to refer to currently accruing trials investigating intratumoral therapy for melanoma

Instructions for Participation

  1. Read the following information before beginning the educational activity.
  2. Complete the Pretest.
  3. View and study all Flash video presentations.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

Accreditation and Credit Designation

Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Complete the test(s) and evaluation by March 24, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from the Intralesional Therapy for Melanoma: Two Steps Forward and One Step Back? symposium have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Sanjiv S. Agarwala
Paid Consultant/Advisory Board – Bristol-Myers Squibb Company
Speaker’s Bureau – Novartis Pharmaceuticals Corporation, sanofi-aventis U.S., Wyeth Pharmaceuticals

Peter Hersey
No relevant financial relationships to disclose

Howard L. Kaufman
Paid Consultant/Advisory Board – BioVex, Neogenix Oncology
Speaker’s Bureau – Novartis Pharmaceuticals Corporation, Schering-Plough Corporation

John Thompson
Research Funding – Provectus Pharmaceuticals, Inc.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your software, follow one of the links listed below:

Macintosh Users
Compatible software includes:

Disclaimer

The views and opinions expressed in this learning activity are those of the presenters and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the presenters and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

©Copyright 2009 by Physicians’ Education Resource.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

All correspondence should be directed to:
Editor, Intralesional Therapy for Melanoma: Two Steps Forward and One Step Back?
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

Educational Grants

An educational grant for this activity was provided by:


  1. Provectus Pharmaceuticals, Inc.